Small-bowel mucosal changes and antibody responses after low- and moderate-dose gluten challenge in celiac disease

TamPub

Näytä suppeat kuvailutiedot

dc.contributor.author Lähdeaho, Marja-Leena -
dc.contributor.author Mäki, Markku -
dc.contributor.author Laurila, Kaija -
dc.contributor.author Huhtala, Heini -
dc.contributor.author Kaukinen, Katri -
dc.date.accessioned 2012-06-17T20:14:47Z
dc.date.available 2012-06-16 09:26:17 -
dc.date.available 2012-06-17T20:14:47Z
dc.date.issued 2011 -
dc.identifier.uri http://tampub.uta.fi/handle/10024/65997
dc.description BioMed Central open access -
dc.description.abstract Background Due to the restrictive nature of a gluten-free diet, celiac patients are looking for alternative therapies. While drug-development programs include gluten challenges, knowledge regarding the duration of gluten challenge and gluten dosage is insufficient. We challenged adult celiac patients with gluten with a view to assessing the amount needed to cause some small-bowel mucosal deterioration. Methods Twenty-five celiac disease adults were challenged with low (1-3 g) or moderate (3-5g) doses of gluten daily for 12 weeks. Symptoms, small-bowel morphology, densities of CD3+ intraepithelial lymphocytes (IELs) and celiac serology were determined. Results Both moderate and low amounts of gluten induced small-bowel morphological damage in 67% of celiac patients. Moderate gluten doses also triggered mucosal inflammation and more gastrointestinal symptoms leading to premature withdrawals in seven cases. In 22% of those who developed significant small- intestinal damage, symptoms remained absent. Celiac antibodies seroconverted in 43% of the patients. Conclusions Low amounts of gluten can also cause significant mucosal deterioration in the majority of the patients. As there are always some celiac disease patients who will not respond within these conditions, sample sizes must be sufficiently large to attain to statistical power in analysis. -
dc.language.iso en -
dc.title Small-bowel mucosal changes and antibody responses after low- and moderate-dose gluten challenge in celiac disease -
dc.type fi=Artikkeli aikakauslehdessä | en=Journal article| -
dc.identifier.urn urn:nbn:uta-3-752 -
dc.identifier.doi 10.1186/1471-230X-11-129 -
dc.type.version fi=Kustantajan versio | en=Publisher's version| -
dc.subject.okm fi=Sisätaudit | en=Internal Medicine| -
dc.administrativeunit fi=Terveystieteiden yksikkö | en=School of Health Sciences| -
dc.administrativeunit fi=Lääketieteen yksikkö | en=School of Medicine| -
dc.journal.title BMC Gastroenterology -
dc.journal.volume 11 -
dc.journal.number 129 -
dc.journal.volumepagerange 1-34 -
dc.oldstats 55 -

Viite kuuluu kokoelmiin:

Näytä suppeat kuvailutiedot